Pay in 4 interest-free payments of $6.12 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy
Contact your healthcare provider if you notice any unusual reactions or side effects
J Pediatr 162 , 10041009 e1001, (2013)
It is also a natural osmoprotectant, meaning that it attracts water away from the protein surface and thus protects them from denaturation and increases their thermodynamic stability
Di Giacomo C, Malfa GA, Tomasello B, Bianchi S, Acquaviva R
January 20, 2023
US$ 21.64
US$ 21.52
US$ 25.73
US$ 28.96
US$ 24.45
US$ 24.51
US$ 21.99
US$ 22.12
US$ 23.84
